nach oben

Erschienen in:

05.02.2022 | Original Article

Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study

verfasst von: Sonia Gatius, Ana Velasco, Mar Varela, Miriam Cuatrecasas, Pedro Jares, Lisa Setaffy, Benjamin Bonhomme, Almudena Santon, Kristina Lindemann, Sabrina Croce, Ben Davidson, Sigurd Lax, Jose Palacios, Xavier Matias-Guiu

Erschienen in: Virchows Archiv | Ausgabe 5/2022

Einloggen, um Zugang zu erhalten

Abstract

Determination of microsatellite instability (MSI) and mismatch repair deficiency (MMRD), respectively, in endometrial carcinomas (ECs) is important for diagnostic and prognostic purposes, identification of Lynch syndrome carriers, and selection of patients for immunotherapy. The Idylla™ MSI assay is fully automated, does not require non-tumoral tissue, and can be performed in about 150 min. Two hundred forty-two formalin-fixed paraffin-embedded (FFPE) EC samples from 7 international centers were tested by the Idylla™ MSI assay and compared to the Promega™ MSI Analysis System and immunohistochemistry (IHC) for MMR proteins. The cases were selected with an enrichment of MSI EC to around 40%. Concordance was 87.5% between the Idylla™ MSI assay and IHC and 88.58% between IHC and Promega™ MSI assay. Concordance between Idylla™ and Promega™ MSI assays was 89.91%. Discordant results occurred more frequently in cases with MSH6 or PMS2 deficiency. Invalid cases occurred with the three techniques (IHC, 7.00%; Promega™ MSI assay, 5.37%; and Idylla™ MSI assay, 2.47%). The concordance rate between Idylla™ MSI assay and the other 2 methods increased to 88.83% for IHC and to 91.22% for the Promega™ MSI assay when the cutoff of instability in the scoring system was moved from 0.5 to 0.3. The Idylla™ MSI assay is a rapid and highly concordant test for MSI in EC. Modification of the Idylla™ scoring system could increase the sensitivity and specificity of the MSI assay for EC analysis.

Matias-Guiu X, Prat J (2013) Molecular pathology of endometrial carcinoma. Histopathology 62:111–123CrossRef

Hampel H, Pearlman R, de la Chapelle A, Pritchard CC, Zhao W, Jones D et al (2021) Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. Gynecol Oncol 160:161–168CrossRef

Broaddus RR, Lynch HT, Chen LM, Daniels MS, Conrad P, Munsell MF et al (2006) Pathologic features of endometrial carcinoma associated with HNPCC: a comparison with sporadic endometrial carcinoma. Cancer 106:87–94CrossRef

Honore LH, Hanson J, Andrew SE (2006) Microsatellite instability in endometrioid endometrial carcinoma: correlation with clinically relevant pathologic variables. Int J Gynecol Cancer 16:1386–1392CrossRef

Shia J, Black D, Hummer AJ, Boyd J, Soslow RA (2008) Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol 39:116–125CrossRef

Luis A. Diaz, Jennifer N. Uram, Hao Wang, Bjarne Bartlett, Holly Kemberling, Aleksandra Eyring, Nilofer Saba Azad, Tianna Dauses, Dan Laheru, James J. Lee, Todd S. Crocenzi, Richard M. Goldberg, George A. Fisher, Tim F. Greten, Christian Frederick Meyer, Amanda Nickles Fader, Deborah Kay Armstrong, Minori Koshiji, Bert Vogelstein, Dung T. Le (2016). Programmed death-1 blockade in mismatch repair deficient cancer independent of tumour histology. J Clin Oncol 34:15_suppl, 3003–3003.

Ott PA, Bang Y-J, Berton-Rigaud D, Elez E, Pishvaian MJ, Rugo HS et al (2016) Pembrolizumab in advanced endometrial cancer: preliminary results from the phase Ib KEYNOTE-028 study. J Clin Oncol 34(15_ suppl):5581CrossRef

The Cancer Genome Atlas Research Network (2013) Integrated genomic characterization of endometrial carcinoma. Nature 497:67–73CrossRef

Piulats JM, Guerra E, Gil-Martín M, Roman-Canal B, Gatius S, Sanz-Pamplona R et al (2017) Molecular approaches for classifying endometrial carcinoma. Gynecol Oncol 145:200–207CrossRef

10.

Talhouk A, McConechy MK, Leung S, Li-Chang HH, Kwon JS, Melnyk N et al (2015) A clinically applicable molecular-based classification for endometrial cancers. Br J Cancer 113:299–310CrossRef

11.

Vermij L, Smit V, Nout R, Bosse T (2020) Incorporation of molecular characteristics into endometrial cancer management. Histopathology 76:52–63CrossRef

12.

León-Castillo A, Britton H, McConechy MK, McAlpine JN, Nout R, Kommoss S et al (2020) Interpretation of somatic POLE mutations in endometrial carcinoma. J Pathol 250:323–335CrossRef

13.

Modica I, Soslow RA, Black D, Tornos C, Kauff N, Shia J (2007) Utility of immunohistochemistry in predicting microsatellite instability in endometrial carcinoma. Am J Surg Pathol 31:744–751CrossRef

14.

Concin N, Matias-Guiu X, Vergote I, Cibula D, Mirza MR, Marnitz S et al (2021) ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma. Int J Gynecol Cancer 154:327–353

15.

Umar A, Boland CR, Terdiman JP, Syngal S, de la Chapelle A, Rüschoff J et al (2004) Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 96:261–268CrossRef

16.

Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T et al (2019) ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 30:1232–1243CrossRef

17.

Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel WL et al (2018) Assessment of tumour sequencing as a replacement for Lynch syndrome screening and current molecular tests for patients with colorectal cancer. JAMA Oncol 4:806–813CrossRef

18.

Hissong E, Crowe EP, Yantiss RK, Chen YT (2018) Assessing colorectal cancer mismatch repair status in the modern era: a survey of current practices and re-evaluation of the role of microsatellite instability testing. Mod Pathol 4:806–813

19.

Middha S, Zhang L, Nafa K, Jayakumaran G, Wong D, Kim HR et al (2018) Reliable pan-cancer microsatellite instability assessment by using targeted next-generation sequencing data. JCO Precis Oncol. https://doi.org/10.1200/PO.17.00084CrossRef

20.

Shia J (2008) Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome: part I. The utility of immunohistochemistry. J Mol Diagnostics 10:293–300CrossRef

21.

Zhao H, Thienpont B, Yesilyurt BT, Moisse M, Reumers J, Coenegrachts L et al (2014) Mismatch repair deficiency endows tumours with a unique mutation signature and sensitivity to DNA double-strand breaks. Elife 3:02725

22.

Li X, Xu J, Li L, Mu X, Wang Y, Li X (2019) Evaluation of a fully automated Idylla test system for microsatellite instability in colorectal cancer. Clin Colorectal Cancer. 18:316–323CrossRef

23.

Lee M, Chun SM, Sung CO, Kim SY, Kim TW, Jang SJ et al (2019) Clinical utility of a fully automated microsatellite instability test with minimal hands-on time. J Pathol Transl Med 53:386–392CrossRef

24.

Zwaenepoel K, Holmgaard Duelund J, De Winne K, Maes V, Weyn C, Lambin S et al (2020) Clinical performance of the Idylla MSI test for a rapid assessment of the DNA microsatellite status in human colorectal cancer. J Mol Diagnostics 22:386–395CrossRef

25.

Samaison L, Grall M, Staroz F, Uguen A (2019) Microsatellite instability diagnosis using the fully automated Idylla platform: feasibility study of an in-house rapid molecular testing ancillary to immunohistochemistry in pathology laboratories. J Clin Pathol 72:830–835CrossRef

26.

De Craene B, Van de Velde J, Bellon E, Gazin M, Rondelez E, Vandenbroeck L et al (2018) Detection of microsatellite instability (MSI) with a novel set of 7 Idylla biomarkers on colorectal cancer samples in a multi-center study. Ann Oncol 29(Supplement):8

27.

Ukkola I, Nummela P, Pasanen A, Kero M, Lepistö A, Kytölä S et al (2021) Detection of microsatellite instability with Idylla™ MSI assay in colorectal and endometrial cancer. Virchows Arch. https://doi.org/10.1007/s00428-021-03082-wCrossRefPubMedPubMedCentral

28.

Siemanowski J, Schömig-Markiefka B, Buhl T, Haak A, Siebolts U, Dietmaier W, Arens N, Pauly N, Ataseven B, Büttner R, Merkelbach-Bruse S (2021) Managing difficulties of microsatellite instability testing in endometrial cancer-limitations and advantages of four different PCR-based approaches. Cancers (Basel) 13:1268CrossRef

29.

Gilson P, Levy J, Rouyer M, Demange J, Husson M, Bonnet C, Salleron J, Leroux A, Merlin JL, Harlé A (2020) Evaluation of 3 molecular-based assays for microsatellite instability detection in formalin-fixed tissues of patients with endometrial and colorectal cancers. Sci Rep 10:16386CrossRef

30.

Pécriaux A, Favre L, Calderaro J, Charpy C, Derman J, Pujals A (2021) Detection of microsatellite instability in a panel of solid tumours with the Idylla MSI Test using extracted DNA. J Clin Pathol 74:36–42CrossRef

31.

Dedeurwaerdere F, Claes KB, Van Dorpe J, Rottiers I, Van der Meulen J, Breyne J, Swaerts K, Martens G (2021) Comparison of microsatellite instability detection by immunohistochemistry and molecular techniques in colorectal and endometrial cancer. Sci Rep 11:12880CrossRef

32.

Hause RJ, Pritchard CC, Shendure J, Salipante SJ (2016) Classification and characterization of microsatellite instability across 18 cancer types. Nat Med 22:1342–1350CrossRef

33.

Wang Y, Shi C, Eisenberg R, Vnencak-Jones CL (2017) Differences in microsatellite instability profiles between endometrioid and colorectal cancers: a potential cause for false-negative results? J Mol Diagnostics 19:57–64CrossRef

34.

Wu X, Snir O, Rottmann D, Wong S, Buza N, Hui P (2019) Minimal microsatellite shift in microsatellite instability high endometrial cancer: a significant pitfall in diagnostic interpretation. Mod Pathol 32:650–658CrossRef

35.

Kuismanen SA, Moisio AL, Schweizer P, Truninger K, Salovaara R, Arola J et al (2002) Endometrial and colorectal tumours from patients with hereditary nonpolyposis colon cancer display different patterns of microsatellite instability. Am J Pathol 160:1953–1958CrossRef

Titel: Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study
verfasst von: Sonia Gatius
Ana Velasco
Mar Varela
Miriam Cuatrecasas
Pedro Jares
Lisa Setaffy
Benjamin Bonhomme
Almudena Santon
Kristina Lindemann
Sabrina Croce
Ben Davidson
Sigurd Lax
Jose Palacios
Xavier Matias-Guiu
Publikationsdatum: 05.02.2022
Verlag: Springer Berlin Heidelberg
Erschienen in: Virchows Archiv / Ausgabe 5/2022
Print ISSN: 0945-6317
Elektronische ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-022-03291-x

Neu im Fachgebiet Pathologie

01.04.2024 | Forensische Traumatologie | CME

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study

Abstract

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2022

Carcinosarcoma of the stomach: four cases that expand the morphologic spectrum of gastric cancer with a primitive phenotype

Transdifferentiation of mantle cell lymphoma into sarcoma with limited neuromuscular differentiation after conventional chemotherapy

T1 bladder carcinoma with variant histology: pathological features and clinical significance

Deeper sections reveal residual tumor cells in rectal cancer specimens diagnosed with pathological complete response following neoadjuvant treatment

Comparing the 2017 ASCO/CAP guideline for gastroesophageal adenocarcinoma surgical specimen to the 2018 ASCO/CAP guideline for breast cancer in assessing the HER2 status in primary mucinous ovarian carcinoma

Novel RGAG1-BCOR gene fusion revealed in a somatic soft tissue sarcoma with a long follow-up

Neu im Fachgebiet Pathologie

Theoretische Grundlagen von Explosionen und Explosionsverletzungen

Auswirkungen vorgeschalteter Laborprozesse auf die Digitalisierung histologischer Schnittpräparate

Knochenmarkhistologie bei Zytopenien

Herausforderungen der Automation bei der quantitativen Auswertung von Leberbiopsien